Review paper

PCSK9: Regulation and Target for Drug Development for Dyslipidemia

Volume: 57, Issue: 1, Pages: 223 - 244
Published: Jan 6, 2017
Abstract
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a secreted zymogen expressed primarily in the liver. PCSK9 circulates in plasma, binds to cell surface low-density lipoprotein (LDL) receptors, is internalized, and then targets the receptors to lysosomal degradation. Studies of naturally occurring PCSK9 gene variants that caused extreme plasma LDL cholesterol (LDL-C) deviations and altered atherosclerosis risk unleashed a torrent of...
Paper Details
Title
PCSK9: Regulation and Target for Drug Development for Dyslipidemia
Published Date
Jan 6, 2017
Volume
57
Issue
1
Pages
223 - 244
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.